Compare Incyte Corporation (INCY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Jones Lang LaSalle Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Jones Lang LaSalle Inc for 71 Days on average.
| INCY | JLL | |
|---|---|---|
Market Cap | $22.85B | $13.95B |
Volume | 1,927,029 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $392.79 |
52-Week Low | $83.80 | $280.16 |
Typical Hold Time | 33 Days | 71 Days |
Enterprise Value | $18.35B | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
JLL trades at $303.14, up 2.18% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $26.12B in 2025 and improving profit margins. Analyst consensus remains bullish with a $450.50 price target, though technical indicators suggest near-term caution.
JLL presents a compelling value opportunity with attractive valuation ratios (P/E 14.54, P/S 0.53) and consistent earnings outperformance. Key risks include real estate market cyclicality and competitive pressures, but strong institutional support and strategic acquisitions support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
